We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

DIASYS DIAGNOSTIC SYSTEMS

  Gold Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





DiaSys Showcases Expanding Reagents and Instrumentation Portfolio at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: The respons940 clinical chemistry analyzer was on display at AACC 2022 (Photo courtesy of DiaSys)
Image: The respons940 clinical chemistry analyzer was on display at AACC 2022 (Photo courtesy of DiaSys)

DiaSys Diagnostic Systems (Holzheim, Germany) is showcasing its expanding product portfolio of analyzers and POCT instruments with a special focus on its reagents, at the 73rd AACC Annual Scientific Meeting & Clinical Lab Expo. Vidan Diagnostics (San Antonio, TX, USA), in partnership with Diasys, is also attending the event where it will feature the recently launched next generation Beta-hydroxybutyrate assay used to assist in the determination of diabetic ketoacidosis (DKA).

At the DiaSys AACC 2022 booth, the focus will be on the company’s reagents HDL-c direct FS, LDL-c direct FS, Cystatin C FS, Procalcitonin FS and CRP FS. The company’s innovative new reagents, HDL-c direct FS and LDL-c direct FS, are homogenous assays for direct determination of high-density lipoproteins (HDL) and low-density lipoproteins (LDL). The high quality reagents offer long calibration and onboard stability of up to four months. Combined with wide measuring ranges and good precision at clinical cut-off points, DiaSys assays HDL-c direct FS and LDL-c direct FS are of high value for clinical-chemistry laboratories.

DiaSys Cystatin C FS is an immunturbidemetric assay, which can be applied on a broad range of clinical chemistry analyzers. The assay is characterized by an outstanding analytical sensitivity in addition to superior correlation with nephelometry. It has excellent onboard and calibration stabilities up to 12 weeks and a high prozone security. The standardized test is essential for reliable kidney diagnosis of clinical-chemistry laboratories.

DiaSys Procalcitonin FS is a fluid-stable, particle enhanced immunoturbidimetric assay with outstanding onboard and calibration stability, providing a convenient workflow on clinical chemistry analyzers. Determinations of PCT in serum and plasma within the measuring range from 0.2 ng/mL to 50 ng/mL can be performed with high precision at clinical cut-off levels for sepsis. The performance is complemented by high tolerance to endogenous interferents and various therapeutics used in sepsis management. Procalcitonin FS shows a good correlation to established methods. Results from ring trials and a publication demonstrate the strengths of the assay.

DiaSys CRP FS is a liquid-stable immunoturbidimetric test with dedicated ready-to-use calibrators and controls. The test results are fully quantitative which allows true differentiation of borderline cases. The test is standardized to the international reference material, has a wide measuring range, high prozone security and excellent correlation to competitor tests. The test is easily applicable to clinical chemistry analyzers with a variety of instrument applications available.

Additionally, DiaSys will demonstrate the respons 940 fully automatic random access analyzer (RAM) with a sample throughput of 400 (640 incl. ISE) tests/hour. Due to durable quartz cuvettes, low reaction volume, maintenance free photometer and intuitively operated software, respons 940 offers the economic use and reliability required in small to medium sized labs. In combination with DiaSys' high quality reagents perfectly matching to respons 940 highest results security and therefore, a minimized number of reruns can be assured.

Vidan’s next generation Beta-hydroxybutyrate assay for reliable ketosis management comprises prefilled reagent kits that make it easy to load directly onto Architect and Beckman AU clinical chemistry systems. Its Lipid Clearing System (LCS) overcomes the burden of lipemia by eliminating turbidity in the sample before a measurement is performed. Its superior stability reduces the frequency of calibration and allows the reagent to stay onboard longer.
 

Related Links:
DiaSys Diagnostic Systems 
Vidan Diagnostics 

New
Gold Supplier
pHOx Analyzer
BioProfile pHOx Analyzer
New
Zika Virus ELISA Test
RecombiLISA Zika IgM ELISA CE
New
Glucose & Lactate Measuremen Device
ecobasic
New
Silver Supplier
Glass Beaker
Globe Glass Beakers, Griffin Style

Print article

Channels

Molecular Diagnostics

view channel
Image: The new multiplex QIAstat-Dx Viral Vesicular Panel is designed to support research and surveillance efforts (Photo courtesy of QIAGEN)

First Syndromic Test Differentiates Between Monkeypox and Five Pathogens with Similar Symptoms

A new syndromic test differentiates between monkeypox and five other pathogens which cause similar symptoms. This first-ever test detects the two known forms of monkeypox virus (the so-called West African... Read more

Industry

view channel
Image: The Accelerate Arc Module & BC kit is registered as an IVD (Photo courtesy of Accelerate Diagnostics)

BD and Accelerate Diagnostics Collaborate to Offer Rapid Antimicrobial Identification and Susceptibility Diagnostics

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and Accelerate Diagnostics, Inc. (Tucson, AZ, USA) have entered into a worldwide commercial collaboration agreement where BD will offer Accelerate's... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.